# Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

> **NCT01386710** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Northwell Health** · enrollment: 54 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Bevacizumab and Carboplatin
- **DRUG:** Bevacizumab and Carboplatin

## Key facts

- **NCT ID:** NCT01386710
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2011-09
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 54 (ESTIMATED)
- **Why stopped:** PI left previous institution study will reopen at new institution.
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386710, "Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01386710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*